Geron Corp (GERN)
| Market Cap | 770.97M-7.0% |
| Revenue (ttm) | 204.56M |
| Net Income | -67.61M |
| EPS | -0.11 |
| Shares Out | 642.47M |
| PE Ratio | n/a |
| Forward PE | 30.00 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 5,137,554 |
| Open | 1.21 |
| Previous Close | 1.21 |
| Day's Range | 1.19 - 1.22 |
| 52-Week Range | 1.04 - 2.01 |
| Beta | 0.61 |
| Analysts | none |
| Price Target | 4.25(+254.17%) |
| Earnings Date | Nov 4, 2026 |
Insiders here have filed 1 Form 4 in the last 90 days, but all of them are share awards, grants or other non-market transactions. Those are compensation, not a decision to buy, so they are not scored.
About GERN
Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology. The company's product pipeline includes RYTELO, a telomerase inhibitor for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia; IMerge which is in Phase 3 clinical trial for the treatment of lower-risk myelodysplastic syndromes; IMpactMF that is in Phase 3 for the treatment of relapsed/refractory myelofibrosis; Impress which is in Phase 2 clinical trial to treat higher risk myelodysplastic syndromes and acute myeloid leukemia (AML); IMproveMF which is in Phase 1 clinical trial for the treatment of frontline myelofibrosis; and IMAGINE which is in phase 1/2 clinical trial for the treatment of relapsed/refractory AML. Geron Corporation was incorporated in 1990 and is headquartered in Foster City, California.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
$GERN stock is featured in our Insider Trades datasets.
→ All Stock ListsRecently reported changes in GERN holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by GERN's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
GERN Estimated quarterly lobbying spending
Source: U.S. Senate LDA
GERN Revenue by Segment
| Segment | Revenue | % of All |
|---|---|---|
| Product revenue, net | $57.47M | 99.99% |
| Royalties | $7.00K | 0.01% |
As of: Q2 2026 (Jun 30, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New GERN patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to GERN from public contracts
Source: USAspending.gov
GERN Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from GERN’s recent data — informational, not investment advice